| 1049 |
Classification and Management of Ischemic Stroke in Patients With Active Cancer: A Scientific Statement From the American Heart Association.
|
2026-02-03 |
121 |
| 1048 |
Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial.
|
2026-02-03 |
116 |
| 1047 |
Switching From Aspirin Monotherapy After Noncardioembolic Stroke: A Systematic Review and Network Meta-Analysis.
|
2026-02-03 |
123 |
| 1046 |
Multiterritory Brain Infarcts, Anticoagulation, and Recurrence After Cryptogenic Stroke: A Subgroup Analysis of the ARCADIA Trial
|
2026-01-02 |
214 |
| 1045 |
Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA)
|
2026-01-02 |
211 |
| 1044 |
Intravenous Thrombolysis Use in the Late Time Window Before Interhospital Transfer for Thrombectomy
|
2026-01-02 |
393 |
| 1043 |
Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
|
2025-11-27 |
702 |
| 1042 |
Stroke Mechanism and Severity After Left Atrial Appendage Occlusion: Insights From the LAAOS III Randomized Clinical Trial
|
2025-11-27 |
337 |
| 1041 |
Impaired Perfusion and Early Ischemic Stroke Recurrence in Symptomatic Intracranial Atherosclerosis: BIORISK ICAS Study
|
2025-11-27 |
314 |
| 1040 |
Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke.
|
2025-10-31 |
445 |
| 1039 |
Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial.
|
2025-10-31 |
364 |
| 1038 |
Optimal Antithrombotics for Ischemic Stroke and Concurrent Atrial Fibrillation and Atherosclerosis: A Randomized Clinical Trial (ATIS-NVAF).
|
2025-10-31 |
361 |
| 1037 |
Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: The HOPE Randomized Clinical Trial
|
2025-10-01 |
518 |
| 1036 |
Revised Diagnostic Criteria for Vascular Cognitive Impairment and Dementia—The VasCog-2-WSO Criteria
|
2025-10-01 |
456 |
| 1035 |
Association of Ischemic Core Hypodensity With Thrombectomy Treatment Effect in Large Core Stroke: A Secondary Analysis of the SELECT2 Randomized Controlled Trial
|
2025-10-01 |
384 |
HOME
LOGIN
